SAL Trading’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q2
Sell
-12,200
Closed -$1.65M 15
2024
Q1
$1.65M Buy
12,200
+6,300
+107% +$834K 1.88% 9
2023
Q4
$795K Buy
+5,900
New +$767K 1.27% 17
2023
Q3
Sell
-99,150
Closed -$14.2M 28
2023
Q2
$14.2M Buy
+99,150
New +$14.6M 15.88% 2
2023
Q1
Sell
-2,300
Closed -$313K 45
2022
Q4
$313K Hold
2,300
0.18% 32
2022
Q3
$253K Hold
2,300
0.11% 43
2022
Q2
$308K Sell
2,300
-14,900
-87% -$1.96M 0.13% 36
2022
Q1
$2.31M Buy
+17,200
New +$2.06M 0.54% 26

Other funds holding AZN

SAL Trading's AZN Position: Q3 2024 in Review

SAL Trading sold out of AstraZeneca (AZN) in Q3 2024, closing a stake of 39,351 shares — an estimated $6.14M sold.

SAL Trading first reported a position in AZN in Q4 2021 and held it in 9 quarters. The position peaked at $11M in Q4 2021. 1,230 funds tracked by Wall St. Rank hold AZN as of Q3 2024.

  • SAL Trading reported no remaining AstraZeneca position as of Q3 2024 after selling out during the quarter.
  • SAL Trading sold 39,351 AstraZeneca shares in Q3 2024, an estimated $6.14M.
  • SAL Trading first reported a position in AstraZeneca in Q4 2021 and held it in 9 quarters.
  • SAL Trading's AstraZeneca position peaked at $11M in Q4 2021.
  • 1,230 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2024.

Based on SAL Trading's 13F filing for Q3 2024, filed 14 Nov 2024.